TR200500302T3 - Makrolidlerin kristalizasyonu ve saflaştırılması. - Google Patents

Makrolidlerin kristalizasyonu ve saflaştırılması.

Info

Publication number
TR200500302T3
TR200500302T3 TR2005/00302T TR200500302T TR200500302T3 TR 200500302 T3 TR200500302 T3 TR 200500302T3 TR 2005/00302 T TR2005/00302 T TR 2005/00302T TR 200500302 T TR200500302 T TR 200500302T TR 200500302 T3 TR200500302 T3 TR 200500302T3
Authority
TR
Turkey
Prior art keywords
macrolides
crystallization
purification
solvent
macloride
Prior art date
Application number
TR2005/00302T
Other languages
English (en)
Inventor
Keri Vilmos
Csorvasi Andrea
Original Assignee
Biogal Gyogyszergyar Rt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogal Gyogyszergyar Rt. filed Critical Biogal Gyogyszergyar Rt.
Publication of TR200500302T3 publication Critical patent/TR200500302T3/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Takrolimus, sirolimus, pimekrolimus ya da everolimus gibi bir makloridin kristalize edilmesi ve saflastirilmasi için bir yöntem temin edilmistir, bu yöntem, 7 ya da üzerinde bir pH'ta, bir makrolid ve bir polar çözücü, depolar aprotik çözücü ya da hidrokarbon çözücü kombinasyonunun temin edilmesi asamasini kapsamaktadir.
TR2005/00302T 2003-03-31 2004-03-31 Makrolidlerin kristalizasyonu ve saflaştırılması. TR200500302T3 (tr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45959103P 2003-03-31 2003-03-31
US46170703P 2003-04-09 2003-04-09
US51288703P 2003-10-20 2003-10-20

Publications (1)

Publication Number Publication Date
TR200500302T3 true TR200500302T3 (tr) 2005-04-21

Family

ID=33162981

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2005/00302T TR200500302T3 (tr) 2003-03-31 2004-03-31 Makrolidlerin kristalizasyonu ve saflaştırılması.

Country Status (10)

Country Link
US (1) US7232486B2 (tr)
EP (1) EP1513847A2 (tr)
JP (1) JP4468943B2 (tr)
KR (1) KR20050114262A (tr)
DE (1) DE04758730T1 (tr)
ES (1) ES2229975T1 (tr)
IL (1) IL170331A (tr)
TR (1) TR200500302T3 (tr)
TW (1) TW200504079A (tr)
WO (1) WO2004089958A2 (tr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306166B1 (en) * 1997-08-13 2001-10-23 Scimed Life Systems, Inc. Loading and release of water-insoluble drugs
EP1817314A1 (en) 2004-12-01 2007-08-15 Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság Non-hygroscopic and powdery amorphous pimecrolimus
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
KR100859670B1 (ko) 2006-09-13 2008-09-23 동국제약 주식회사 타크로리무스를 고수율 및 고순도로 정제하는 방법
WO2008057511A2 (en) * 2006-11-06 2008-05-15 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Ascomycin and pimecrolimus having reduced levels of desmethylascomycin and 32-deoxy-32-epichloro-desmethylascomycin respectively, and methods for preparation thereof
RU2009122202A (ru) * 2006-11-10 2010-12-20 Биокон Лимитед (In) Чистая форма рапамицина и способ ее выделения и очистки
ES2393639T3 (es) 2007-01-21 2012-12-26 Hemoteq Ag Producto médico para tratar cierres de conductos corporales y prevención de nuevos cierres
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
US20110275798A1 (en) * 2009-01-21 2011-11-10 Rakesh Bhaiyyaram Mendhe Method for Determination of Sirolimus Stability and Process for Preparing Its Stable Form
US10369256B2 (en) 2009-07-10 2019-08-06 Boston Scientific Scimed, Inc. Use of nanocrystals for drug delivery from a balloon
JP5933434B2 (ja) 2009-07-17 2016-06-08 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． 薬剤送達バルーンの製造方法
WO2011081712A1 (en) * 2009-12-31 2011-07-07 Boston Scientific Scimed, Inc. Cryo activated drug delivery and cutting balloons
EP2611476B1 (en) 2010-09-02 2016-08-10 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
WO2013022458A1 (en) * 2011-08-05 2013-02-14 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
WO2013028208A1 (en) 2011-08-25 2013-02-28 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
CN103159812B (zh) * 2011-12-08 2016-03-23 湖南中创化工股份有限公司 一种从红霉素水溶液中提取红霉素的方法
WO2014072984A1 (en) 2012-11-06 2014-05-15 Natco Pharma Limited Improved process for isolation and purification of rapamycin from fermentation broth
CN102942607A (zh) * 2012-11-28 2013-02-27 宁夏启元药业有限公司 一种复合溶剂结晶红霉素的方法
EP2972258B1 (en) 2013-03-15 2021-08-04 Biosensors International Group, Ltd. Purification of rapamycin derivatives
US9439892B2 (en) 2013-05-16 2016-09-13 Surmodics, Inc. Macrolide particulates, methods for preparation, and medical devices associated therewith
CA2915704C (en) 2013-06-12 2022-06-21 Surmodics, Inc. Solvent methods for preparing crystalline macrolide particulates, compositions, and articles containing particulates
US10098846B2 (en) 2016-03-31 2018-10-16 Surmodics, Inc. Drug-containing particulate composition with cationic agent, associated medical devices, and methods for treatment
US11123459B2 (en) 2016-12-16 2021-09-21 Surmodics, Inc. Hydrophobic active agent particle coatings and methods for treatment
US11795146B2 (en) * 2021-10-11 2023-10-24 Anebulo Pharmaceuticals, Inc. Crystalline forms of a cannabinoid receptor type 1 (CB1) modulator and methods of use and preparation thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1666924A (en) 1924-06-23 1928-04-24 John J Selb Arch support
DE2121517C3 (de) * 1971-04-30 1974-06-27 Leningradskij Nautschno-Issledowatelskij Institut Antibiotikow, Ssr, Leningrad (Sowjetunion) Verfahren zur Gewinnung von Amphoterizin B
US3993749A (en) 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US4160861A (en) * 1977-10-03 1979-07-10 Merck & Co., Inc. Method for the separation of antibiotic macrolides
US4543334A (en) * 1983-12-16 1985-09-24 Pfizer Inc. Streptomyces capable of producing neutral macrolide antibacterial agents
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
JPH0216662A (ja) * 1988-07-05 1990-01-19 Nec Corp 代替端末コントロール装置
JP2639737B2 (ja) * 1990-01-23 1997-08-13 寳酒造株式会社 新規ｒ１０６類化合物
US5116756A (en) 1991-01-28 1992-05-26 Merck & Co., Inc. Process for producing FK-506
EP0582690A1 (en) 1991-04-11 1994-02-16 Pfizer Inc. Novel immunosuppressant agent from streptomyces braegensis
US5091389A (en) * 1991-04-23 1992-02-25 Merck & Co., Inc. Lipophilic macrolide useful as an immunosuppressant
JPH07500613A (ja) * 1992-03-02 1995-01-19 ファイザー・インコーポレーテッド 免疫抑制剤及び抗真菌剤としてのマクロライドのデソサミノ誘導体
UA41884C2 (uk) * 1993-11-05 2001-10-15 Амерікан Хоум Продактс Корпорейшн Спосіб відокремлення рапаміцину від кислотних, основних та неполярних нейтральних домішок, присутніх в концентраті екстрактів ферментаційного бульйону або маточних розчинів
US5622866A (en) * 1994-06-23 1997-04-22 Merck & Co., Inc. Expression cassettes useful in construction of integrative and replicative expression vectors for Streptomyces
GB9618952D0 (en) * 1996-09-11 1996-10-23 Sandoz Ltd Process
GB9826882D0 (en) * 1998-12-07 1999-01-27 Novartis Ag Organic compounds
ES2177373B1 (es) * 1999-11-26 2003-11-01 Astur Pharma Sa Preparacion de azitromicina en su forma no cristalina
EP1263979A4 (en) * 2000-02-24 2003-05-21 Biogal Gyogyszergyar METHOD FOR CLEANING FERMENTATION BREW
US7452692B2 (en) * 2002-02-13 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method for extracting a macrolide from biomatter
JP4261365B2 (ja) * 2002-02-13 2009-04-30 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ 生物学的物質からのマクロライドの抽出方法

Also Published As

Publication number Publication date
ES2229975T1 (es) 2005-05-01
KR20050114262A (ko) 2005-12-05
US20040226501A1 (en) 2004-11-18
WO2004089958A3 (en) 2005-01-13
US7232486B2 (en) 2007-06-19
WO2004089958A2 (en) 2004-10-21
JP4468943B2 (ja) 2010-05-26
WO2004089958B1 (en) 2005-03-03
TW200504079A (en) 2005-02-01
DE04758730T1 (de) 2005-06-23
JP2006522018A (ja) 2006-09-28
IL170331A (en) 2010-04-15
EP1513847A2 (en) 2005-03-16

Similar Documents

Publication Publication Date Title
TR200500302T3 (tr) Makrolidlerin kristalizasyonu ve saflaştırılması.
IL182872A0 (en) Ascomycin crystalline forms and preparation thereof
DK1661905T3 (da) Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype
WO2002018335A1 (fr) Derives d'amine cyclique
EP1731523A4 (en) THIAZOLOPYRIMIDINE DERIVATIVE
PE20080138A1 (es) Procesos para preparar conjugados de polietilen glicol solubles en agua de inmunosupresores macrolidos
ATE514686T1 (de) Neue oxazolidinonderivate
WO2005060972A3 (en) Pyrrolo [2,3-d] pyrimidine compounds for treating transplant rejection
UA84881C2 (ru) Аморфный 42-эфир рапамицина и 3-гидрокси-2-(гидроксиметил)-2-метилпропионовой кислоты и фармацевтическая композиция, содержащая его
TW200613290A (en) Substituted urea compounds
WO2007044050A3 (en) 1h-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
DE60309701D1 (de) 2-ureido-6-heteroaryl-3h-benzoimidazol-4-carbonsäurederivate und verwandte verbindungen als gyrase und/oder topoisomerase iv inhibitoren zur behandlung von bakteriellen infektionen
AU2010232388A1 (en) Hydroxythienoquinolones and related compounds as anti-infective agents
WO2006120563A3 (en) Antibacterial agents
WO2005111080A3 (en) Methods for reducing biofilm formation in infectious bacteria
NO981250L (no) Nye derivater av cyklodepsipeptid PF1022-substans
WO2005037839A8 (fr) Composes derives de norcantharidine, leurs procedes de preparation, les compositions les contenant et leurs utilisations.
HUP0004793A2 (hu) Eljárás alatrofloxacin-mezilát tisztítására és alkalmazására, a vegyületet tartalmazó parenterális készítmények
WO2008006113A3 (en) Novel belactosin derivatives as therapeutic agents/biological probes and their synthesis
ATE254626T1 (de) Antibiotische caprazamycine und verfahren zu deren herstellung
ATE279191T1 (de) Trizyklische dihydrobenzofurane, verfahren zu deren herstellung und mittel
WO1999048461A3 (en) Substituted aromatic compounds for treatment of antibiotic resistant infections
CA2543665A1 (en) Cci-779 for treating mantle cell lymphoma
TWI265151B (en) Method of purifying niobium compound and/or tantalum compound
WO2008036420A3 (en) 9-(heteroaryl)-isothiazolo[5,4-b]quinoline-3,4-diones and related compounds as anti-infective agents